CYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds CYTK Investors to Contact the Firm Before November 17th

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, stating it would occur in the second half of 2025 based on a September 26, 2025 PDUFA date, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [8]. - On May 6, 2025, it was revealed during an earnings call that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [8]. Next Steps - Investors who purchased Cytokinetics shares between December 27, 2023, and May 6, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].